Clinical Trial · NCT04457258

PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation

Overview

This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with sarcoma. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi. Because some cancers take up 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Early Phase 1

Contacts

Maria Contreras (Clinical Research Coordinator)

mmcontreras@mednet.ucla.edu

310-825-7336

Hamzah Alam (Clinical Research Coordinator)

halam@mednet.ucla.edu

310-206-7372

ClinicalTrials.gov

NCT04457258

Drug / Compound

Isotope(s):

Target(s):

Eligibility

Inclusion

Patients who are ≥ 18 years old at the time of the radiotracer administration.
Scheduled for a surgical excision or biopsy of a suspected sarcoma primary, suspected recurrent or metastatic lesion
Patients who can provide written informed consent.
Patients who are able to remain still for duration of imaging procedures (up to one hour for each).

Exclusion

Patients with any new cancer therapy between the baseline 18F-FDG PET/CT and the investigational FAPI PET/CT
Patient is pregnant or nursing.
Patient has underlying disease which might interfere with the collection of high quality data

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…